MyMD Pharmaceuticals Valuation
| MYMDDelisted Stock | USD 1.82 0.02 1.09% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. MyMD Pharmaceuticals secures a last-minute Real Value of $1.69 per share. The latest price of the firm is $1.82. Our model forecasts the value of MyMD Pharmaceuticals from analyzing the firm fundamentals such as current valuation of 2.99 M, and Return On Equity of -1.01 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that MyMD Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of MyMD Pharmaceuticals is based on 3 months time horizon. Increasing MyMD Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the MyMD stock is determined by what a typical buyer is willing to pay for full or partial control of MyMD Pharmaceuticals. Since MyMD Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of MyMD Stock. However, MyMD Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.82 | Real 1.69 | Hype 1.82 |
The real value of MyMD Stock, also known as its intrinsic value, is the underlying worth of MyMD Pharmaceuticals Company, which is reflected in its stock price. It is based on MyMD Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of MyMD Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of MyMD Pharmaceuticals helps investors to forecast how MyMD stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MyMD Pharmaceuticals more accurately as focusing exclusively on MyMD Pharmaceuticals' fundamentals will not take into account other important factors: MyMD Pharmaceuticals Total Value Analysis
MyMD Pharmaceuticals is now expected to have valuation of 2.99 M with market capitalization of 4.31 M, debt of 48.87 K, and cash on hands of 5.62 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the MyMD Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.99 M | 4.31 M | 48.87 K | 5.62 M |
MyMD Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of MyMD is to check how much profit was generated for every dollar of assets it reports. MyMD Pharmaceuticals secures a negative usage of assets of -0.5 %, losing $0.005046 for each dollar of assets held by the firm. Ineffective asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of MyMD Pharmaceuticals shows how unsuccessful it operates for each dollar spent on its assets.MyMD Pharmaceuticals Ownership Allocation
MyMD Pharmaceuticals secures 6.61 % of its outstanding shares held by insiders and 6.62 % owned by institutional investors.MyMD Pharmaceuticals Profitability Analysis
Net Loss for the year was (4 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates MyMD Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in MyMD Pharmaceuticals and how it compares across the competition.
About MyMD Pharmaceuticals Valuation
The delisted stock valuation mechanism determines MyMD Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of MyMD Pharmaceuticals. We calculate exposure to MyMD Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of MyMD Pharmaceuticals's related companies.MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company was founded in 2014 and is headquartered in Baltimore, Maryland. Mymd Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.
MyMD Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as MyMD Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.5 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |